Form 4: Day One Biopharmaceuticals Executive Sells 10,000 Shares

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 10,000 shares of common stock on March 25, 2024, according to a Form 4 filing.

Summary

• Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 10,000 shares of common stock on March 25, 2024.
• The shares were sold at a weighted average price of $16.0055, with individual sales ranging from $16.00 to $16.04 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2023.
• Following the transaction, Blackman directly owns 1,184,662 shares of Day One Biopharmaceuticals.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating an insider stock sale. It doesn't inherently convey positive or negative sentiment, but rather reports a factual transaction.

Industry Context

Insider sales are a common occurrence in publicly traded companies. They can be for a variety of reasons, including diversification, tax planning, or personal expenses. It's important to consider the context of the sale, such as the size of the sale relative to the insider's holdings, the timing of the sale, and any other relevant information.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price, although the existence of a 10b5-1 plan mitigates this concern.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be minimal.

Key Dates